Drug intelligence / Profile preview

Optive, Systane

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Optive and Systane are two distinct brands of over-the-counter (OTC) lubricant eye drops, also known as artificial tears, used for the symptomatic relief of dry eye syndrome (keratoconjunctivitis sicca). Optive, developed by Allergan (now part of AbbVie), is a dual-action formula containing carboxymethylcellulose sodium (CMC) and glycerin; it acts as a lubricant and osmoprotectant to stabilize the tear film and protect the ocular surface. Systane, developed by Alcon, is typically formulated with polyethylene glycol 400 and propylene glycol, utilizing a unique hydroxypropyl guar (HP-guar) gelling system that forms a protective matrix on the eye surface upon contact with tears. These products are frequently compared in clinical settings, such as Phase 4 trials sponsored by Innovative Medical, to evaluate subjective patient preferences, duration of action, and frequency of use in mild to moderate dry eye cases.

Brand names
OptiveSystane

Beyond the preview

Go deeper on Optive, Systane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optive, Systane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call